Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Under the terms of the agreement, Oryx's shareholders received U.S. $50 million (approximately 2.5 times projected 2008 sales) and may become entitled to receive subsequent payments up to U.S. $20 million upon accomplishment of various Canadian regulatory milestones.
"We are excited to have closed the Oryx acquisition, which creates a commercial platform for Sepracor in the Canadian specialty pharmaceutical market. Given the growth in our research and development pipeline and the planned submissions of products such as LUNESTA(R), BROVANA(R) and eslicarbazepine for marketing approval in Canada, this acquisition should enable us to fully leverage our current and future product opportunities in this market in addition to the existing Oryx portfolio," said Adrian Adams, President and Chief Executive Officer of Sepracor. "We are also pleased to bring on board an experienced management team and commercial infrastructure that has demonstrated excellent regulatory and product launch successes."
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. Sepracor's drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Currently marketed products include LUNESTA(R) brand eszopiclone, XOPENEX(R) brand levalbuterol HCl Inhalation Solution, XOPENEX HFA(R) brand levalbuterol tartrate Inhalation Aerosol, BROVANA(R) brand arformoterol tartrate Inhalation Solution and OMNARIS(TM) brand ciclesonide Nasal Spray. Sepracor's corporate headquarters are located in Marlborough, Massachusetts.
This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to Oryx's projected 2008 revenues; the planned submissions of products such as LUNESTA, BROVANA and eslicarbazepine for marketing approval in Canada; and the acquisition enabling Sepracor to fully leverage its current and future product opportunities in Canada. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: difficulties integrating Oryx as a part of the Sepracor organization and the diversion of management's attention from other matters as a result of such integration efforts; Sepracor's ability to fund, and the results of, further clinical trials with respect to products under development for sale in Canada; the timing and success of submission, acceptance, and approval of regulatory filings in Canada; the clinical benefits and commercial success of Sepracor's products and the products marketed by Oryx; the ability of the company to attract and retain qualified personnel; and certain other factors that may affect future operating results that are detailed in Sepracor's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 filed with the Securities and Exchange Commission.
In addition, the statements in this press release represent Sepracor's expectations and beliefs as of the date of this press release. Sepracor anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while Sepracor may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Sepracor's expectations or beliefs as of any date subsequent to the date of this press release.
Angiomax is a registered trademark of The Medicines Company. Cubicin is a registered trademark of Cubist Pharmaceuticals, Inc. Trileptal is a registered trademark of Novartis AG. Restoril is a registered trademark of Novartis Pharma Canada Inc. Niaspan and Advicor are registered trademarks of Kos Life Sciences LLC. Naprelan is a registered trademark of Elan Corporation PLC. Lunesta, Xopenex, Xopenex HFA and Brovana are registered trademarks of Sepracor Inc. Omnaris is a trademark of Nycomed GmbH. For a copy of this release or any recent release, visit Sepracor's web site at www.sepracor.com.
Adrian Adams, 508-481-6700
Chief Executive Officer
Jonae R. Barnes, 508-481-6700
Sr. Vice President
Posted: June 2008